Hologic — May 2, 2024 release

“With a strong first half of fiscal 2024, we enter the second half of the year in a position of strength and confidence to deliver on our financial commitments for the year.” Hologic’s financial guidance for the second quarter and full year 2024 is shown in the table below. The guidance is based on a full year non-GAAP tax rate of approximately 19.75%, and diluted shares outstanding of approximately 238 million for the full year. Constant currency guidance assumes that foreign exchange rates are the same in fiscal 2024 as in fiscal 2023. Organic revenue guidance for fiscal 2024 is in constant currency and excludes the divested Blood Screening and SSI ultrasound imaging businesses. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the acquisition. In fiscal 2024, all prior transactions are included in Hologic’s organic revenue base. Organic revenue excluding COVID-19 is in constant currency and is organic revenue excluding COVID-19 assay revenue, COVID-19 related revenue, and discontinued product sales in Diagnostics.       Current Guidance*   Previous Guidance         Guidance $   Reported % Increase (Decrease) Constant Currency % Increase (Decrease) Organic excluding COVID-19 % Increase   Guidance $   Fiscal 2024                     Revenue     $4,000 - $4,050   (0.8%) to 0.5% (0.8%) to 0.4% 5.1% to 6.5%   $3,990-$4,065   GAAP EPS     $3.45 - $